Because the 2026 buying and selling 12 months rolls on, I’d wish to cease for a second and say…
What a freakin’ begin!
As of final week, Karim and I’ve put up among the strongest numbers within the six-year historical past of The Conflict Room.
Thus far in 2026, we’ve hit winners on 89 out of 107 whole trades, good for an eye-popping 83% win fee and a median return per commerce about 14%.
Even higher…
We’ve gained 25 out of 26 trades up to now in April.
So, let’s maintain this momentum rolling!
Which means diving into some super-speculative positions that might proceed to profit from the present administration’s distinctive method to healthcare.
Particularly…
Let’s talk about the truth of the brand new MAHA motion.
As I’m certain you already know, there’s a brand new White Home initiative aimed toward accelerating scientific critiques of psychedelics.
On April 18, President Trump signed an Govt Order particularly directing federal companies to streamline regulatory pathways and increase entry to psychedelic medicines for sufferers the place different therapies have failed.
Army veterans affected by PTSD are on the heart of that push.
Whereas unorthodox and tremendous speculative, listed below are among the corporations that might profit from any type of optimistic sector information within the close to time period…
AtaiBeckley (ATAI): The results of a $390 million merger between atai Life Sciences and Beckley Psytech that was accomplished in November 2025, this firm is creating a nasal spray utilizing an artificial type of 5-MeO-DMT. It’s the compound discovered within the Sonoran Desert toad that Hunter Biden and Mike Tyson have each publicly credited for private transformations.
The FDA granted the drug Breakthrough Remedy designation in October 2025. Section 3 trials had been initiated in Q2 2026. Shares are already up 196% over the past 12 months.
Compass Pathways (CMPS): It’s engaged on treatment-resistant despair with a lab-made compound of psilocybin, the lively ingredient discovered naturally in magic mushrooms.
Compass is accelerating its launch timeline by 9 to 12 months after a optimistic FDA assembly, placing it on monitor to be the primary firm with a shot at FDA approval for a psilocybin product in late 2026 or early 2027. Shares are up 117% within the final 12 months.
Definium Therapeutics (DFTX): Previously often called MindMed, this firm rebranded in January 2026 and has a late-stage trial utilizing a pharmaceutical-grade formulation of LSD for despair and anxiousness.
Three Section 3 readouts are coming within the subsequent six months, with MDD knowledge anticipated late Q2, and two GAD research studying out in Q3.
They’re additionally learning whether or not R-MDMA, a type of the celebration drug Molly, can assist sufferers with autism spectrum dysfunction. Definium publicly applauded the White Home Govt Order two weeks in the past and named it a direct catalyst for its pipeline. Shares are up 283%.
Now, earlier than you pull up these tickers and purchase…
None of those three corporations has any significant revenues, however with a extra favorable regulatory setting and a White Home actively pushing to speed up psychedelic drugs approvals, I assumed I’d convey them to your consideration for doable super-speculative upside MAHA performs.
YOUR ACTION PLAN
If any type of optimistic information hits the airways on any of those three shares, you possibly can simply see the upside beneficial properties proceed.
The near-term binary occasions to look at are Definium’s three Section 3 readouts between now and Q3 2026 and any additional White Home or FDA bulletins on psychedelic drugs coverage.
Put all three in your speculative watch listing for pending information proper now!